Cargando…

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics

BACKGROUND AND AIM: Programmed cell death‐ligand 1 (PD‐L1) immunohistochemistry score has been approved as the predictive biomarker for anti‐PD1/PD‐L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti‐PD1/P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mou, Haibo, Yang, Qiu‐an, Yu, Lanfang, Wang, Ting, Liu, Kui, Shen, Rong, Pan, Xuedong, Dai, Yi, Wan, Qing, Zhou, Fangling, Qian, Lili, Chen, Donglin, Yau, Thomas, Dong, Xiaowei, Wang, Xuemei, Wang, Shuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Experimental Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518358/ https://www.ncbi.nlm.nih.gov/pubmed/33656759 http://dx.doi.org/10.1111/jgh.15475

Ejemplares similares

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification
por: Fan, Zhongqi, et al.
Publicado: (2023)

Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas
por: Zhang, Qi, et al.
Publicado: (2019)

Coordinative control of G2/M phase of the cell cycle by non-coding RNAs in hepatocellular carcinoma
por: Shi, Jun, et al.
Publicado: (2018)

PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma
por: Lu, Li-Gong, et al.
Publicado: (2022)

Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma
por: Cai, Jiabin, et al.
Publicado: (2019)

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
por: Xiong, Zhewen, et al.
Publicado: (2023)

Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
por: Amaddeo, Giuliana, et al.
Publicado: (2015)

STK33 promotes hepatocellular carcinoma through binding to c-Myc
por: Yang, Tian, et al.
Publicado: (2016)

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma
por: Jühling, Frank, et al.
Publicado: (2021)

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas
por: Govaere, Olivier, et al.
Publicado: (2014)

Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis
por: Lee, Jun Ho, et al.
Publicado: (2019)

Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation
por: Chen, Ling, et al.
Publicado: (2023)

Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma
por: Garnelo, Marta, et al.
Publicado: (2017)

Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk?
por: Tholey, Danielle M, et al.
Publicado: (2017)

Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage
por: Perugorria, Maria J, et al.
Publicado: (2019)

TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
por: Esparza-Baquer, Aitor, et al.
Publicado: (2021)

Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis
por: Cullen, Katherine, et al.
Publicado: (2023)

Epigenetic identification of mitogen-activated protein kinase 10 as a functional tumor suppressor and clinical significance for hepatocellular carcinoma
por: Tang, Liping, et al.
Publicado: (2021)

Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2019)

Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma
por: Péneau, Camille, et al.
Publicado: (2022)

Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma
por: Liu, Jinkai, et al.
Publicado: (2022)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2011)

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma
por: Chan, Tim Hon Man, et al.
Publicado: (2014)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study
por: Ladenheim, Maya R, et al.
Publicado: (2016)

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study
por: De Toni, Enrico N, et al.
Publicado: (2020)

Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort
por: Luo, Laihui, et al.
Publicado: (2023)

Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury
por: Zhuang, Yuan, et al.
Publicado: (2020)

The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway
por: Chen, Jianxiang, et al.
Publicado: (2016)

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
por: Bollard, Julien, et al.
Publicado: (2017)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
por: Rao, Jianhua, et al.
Publicado: (2022)

Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia
por: Kim, Yoona A, et al.
Publicado: (2016)

New case of syncytial giant-cell variant of hepatocellular carcinoma in a pediatric patient with HNF1B deficiency: does it fit with the syndrome?
por: Pinon, Michele, et al.
Publicado: (2022)

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study
por: Buch, Stephan, et al.
Publicado: (2023)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tmc7mp2a7tvcr322cgfeun3kpq